0000358654
Donate

Reimbursement status:
Reimbursement with restrictions

Cancer: Lymphocytic leukaemia

Indication:

Ibrutinib as a single agent is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XE
L01XE Protein kinase inhibitors
EMA approval status :
Approved
EMA approval date :
2014-10-21
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No